Our Data
Fiskus et al. “Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML” AACR, April 2023
Bonte et al. “Discovery and Characterization of Potent, Selective CBP Degraders” AACR, April 2023
Collins et al. “The dual BRM/BRG1 (SMARCA2/4) inhibitor FHD-286 induces differentiation in preclinical models of acute myeloid leukemia (AML)” AACR, April 2023
Daniels. “Considerations for heterobifunctional degraders and translation to clinic” AACR, April 2023
Sappal et al. “Discovery and Characterization of Novel, Selective EP300 Degraders” AACR, April 2023
Taherbhoy. “Targeting Transcription Factor – BAF Interactions in Cancer” Drug Discovery Chemistry Meeting, April 2023
Netherton. “Discovery of FHD-609: A Potent and Selective Heterobifunctional Degrader of BRD9” Drug Discovery Chemistry Meeting, April 2023
Sherbanee et al. “Characterizing Compound Behavior at Foghorn Therapeutics” SLAS, February/March 2023
Fiskus et al. “Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPasesBRG1 and BRM by FHD-286 in cellular models of AML of diverse genetic background” ASH, December 2022
Collins et al. “Preclinical validation of target engagement assays and investigation of mechanistic impacts of FHD-609, a clinical-stage BRD9 degrader being developed for the treatment of synovial sarcoma” 2022 Connective Tissue Oncology Society Annual Meeting, November 17, 2022
Ichikawa et al. “Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models” Society for Immunotherapy of Cancer 37th Annual Meeting, November 11, 2022
Daniels. “Progressing degraders towards and through the clinic” Hanson Wade’s 5th Annual Targeted Protein Degradation Summit, October 26, 2022
Wan et al. “Biomarkers identified in preclinical studies evaluating the BRG1/BRM ATPase inhibitor FHD-286 in uveal melanoma” The 19th International Congress of the Society for Melanoma Research, October 17-20, 2022
Hentemann et al. “Pharmacological profile and anti-tumor properties of FHD-286, a novel BAF inhibitor for the treatment of transcription factor-driven cancers” AACR, April 2022
Sandoval et al. “Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML” AACR, April 2022
Centore et al. “Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers” AACR, April 2021
Centore, Sandoval, Mendes Soares, Kadoch and Chan. “Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies” TIGS 1709 August 29, 2020
Michel et al. “A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation” Nat. Cell Biol. 2018 Dec; 20(12): 1410–1420
Kadoch & Crabtree. “Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics” Science Advances 12 Jun 2015: Vol. 1, no. 5, e1500447
Hodges, Kirkland, and Crabtree. “The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer” Advance July 13, 2016
Valencia and Kadoch. “Chromatin regulatory mechanisms and therapeutic opportunities in cancer” Nat Cell Biol. 2019 Feb; 21(2): 152–161
Sandoval et al. “Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis” 2018, Molecular Cell 71, 554–566, August 16, 2018